PracticeUpdate: Haematology & Oncology

VOL. 2 • NO. 1 • 2017


ISSN 2206-463X

2016 Top Stories in Oncology

EDITOR’S PICKS Atezolizumab for advanced urothelial carcinoma, adjuvant sunitinib for high- risk RCC after nephrectomy and 10-year outcomes for localised prostate cancer 8 Complete remissions with anti-CD22 CAR-T in children with relapsed/refractory ALL Patients who reached target second-maintenance- dose antithrombin III level achieved complete response of veno-occlusive disease Serial evaluation of plasma circulating tumour DNA can detect molecular response to treatment for metastatic breast cancer PIK3CA mutation testing from ctDNA may potentially be used as a surrogate for unknown or wild-type mutation status when tissue is unavailable SABCS 2016 22 ASH 2016 10

Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian Network meta-analysis Annals of Oncology This systematic review and meta-analysis found that dexrazoxane (based on moderate- quality data) and angiotensin antagonists (based on low-quality data) are potentially effective in preventing cardiotoxicity associated with anthracycline treatment.

Vitamin D receptor genotype, vitamin D3 supplementation, and risk of colorectal adenomas: a randomized clinical trial JAMA Oncology For the prevention of advanced colorectal adenomas, the benefits of vitamin D3 supplementation may vary based on the vitamin D receptor genotype.

Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy New England Journal of Medicine The study results showed that sunitinib

significantly lengthened disease-free survival in patients with locoregional clear cell RCC at high risk for tumour recurrence following nephrectomy, although this benefit was accompanied by increased adverse events. 9



Made with